A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, Safety, and Tolerability of MK0873 in Rheumatoid Arthritis
Latest Information Update: 06 May 2022
At a glance
- Drugs MK 0873 (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 01 Aug 2021 This trial has been completed in Spain, according to European Clinical Trials Database record.
- 03 Nov 2009 Actual patient number (106) added and official title amended as reported by ClinicalTrials.gov.
- 03 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.